Federal laws have enhanced pediatric drug studies
Federal laws that motivate or require drug and biologic developers to conduct pediatric studies have yielded beneficial information to guide the use of medications in children, says a new report by the Institute of Medicine. Still, studies involving children continue to be limited, especially in certain areas such as medications' use in newborns and long-term safety and effectiveness in children. The report identifies ways that Congress and the U.S. Food and Drug Administration could further improve the utility of clinical information obtained from pediatric studies, including expanding innovative strategies to research drugs and biologics in children, using FDA's authority to require long-term pediatric studies of possible safety risks, and giving FDA flexibility to impose sanctions for unreasonably delayed studies.
Conducting research with children is inherently more difficult than with adults. Pediatric patients also offer drug companies a much smaller market and potential economic return. Clinicians often treat children with drugs that have been approved for use with adults but have not been studied with children, even though the drugs may have different risk-benefit profiles for pediatric patients. Recognizing a shortage in knowledge of how medications affect children, Congress has sought to increase pediatric studies of medications under two laws, the Best Pharmaceuticals for Children Act (BPCA), which offers companies economic incentives to study medications in children, and the Pediatric Research Equity Act (PREA), which requires such studies in specific situations. Both laws are due for reauthorization this year. As specified by Congress, FDA asked IOM to review certain aspects of studies that have been conducted under the laws.
The laws have had positive effects, noted the committee that wrote the report. They have spurred the development of helpful information about the uses of therapies in pediatric patients and have expanded access to information from these studies, including FDA reviews of clinical data submitted by study sponsors. FDA reviewers generally have been thorough in assessing the efficacy of drugs, evaluating adverse events, and reaching conclusions about the safety profile of drugs studied in children, the committee concluded.
To further enhance the impact of the legislation, the report suggested that FDA consider more frequent use of its authority to require sponsors to undertake long-term follow-up studies after products have been approved for market. Because children's bodies and minds are continuing to develop and because some therapies for chronic conditions may be used for many years, pediatric studies of drug safety and effectiveness over the long term are important, but they are not commonly required.
Newborn children, especially premature infants, are particularly vulnerable to drug-induced harm and are especially difficult to study. Many drugs used with neonates are older medications, and the incentives and requirements of BPCA and PREA do not apply to them. To promote studies of newer and more widely used drugs that have not been adequately evaluated in these youngest patients, Congress could provide additional resources for short- and long-term neonatal drug studies through the existing BPCA program at the National Institutes of Health, the report says.
Congress extended the incentives of BPCA to biological therapies in 2010. It is too early to assess the effects of the law on this therapeutic category, but the committee found that most biologics either have been or are being studied with children.
Although companies have stepped up their efforts to conduct research involving children in response to BPCA and PREA, it can still take a long time for needed information to be generated, the report noted. To improve the timeliness of pediatric studies, Congress could specify that sponsors submit their plans for pediatric studies at the end of phase II trials involving adults. To address concerns that FDA has limited ability to require completion of studies in children, Congress could consider providing FDA with more flexibility to impose sanctions, including monetary penalties, for unreasonably delayed studies.
Provided by National Academy of Sciences
- Safe prescribing information for children in Canada often hard to find Jun 13, 2011 | not rated yet | 0
- Post-marketing studies finding adverse events in drugs used in children Sep 02, 2008 | not rated yet | 0
- Docs try to close info gap on kids' meds Nov 23, 2007 | not rated yet | 0
- FDA OKs 50th & 51st anti-retroviral drugs Aug 14, 2007 | not rated yet | 0
- Drug to treat HIV in children shows promise via national study Jan 09, 2012 | not rated yet | 0
- Motion perception revisited: High Phi effect challenges established motion perception assumptions Apr 23, 2013 | 3 / 5 (2) | 2
- Anything you can do I can do better: Neuromolecular foundations of the superiority illusion (Update) Apr 02, 2013 | 4.5 / 5 (11) | 5
- The visual system as economist: Neural resource allocation in visual adaptation Mar 30, 2013 | 5 / 5 (2) | 9
- Separate lives: Neuronal and organismal lifespans decoupled Mar 27, 2013 | 4.9 / 5 (8) | 0
- Sizing things up: The evolutionary neurobiology of scale invariance Feb 28, 2013 | 4.8 / 5 (10) | 14
Pressure-volume curve: Elastic Recoil Pressure don't make sense
5 hours ago From pressure-volume curve of the lung and chest wall (attached photo), I don't understand why would the elastic recoil pressure of the lung is...
If you became brain-dead, would you want them to pull the plug?
22 hours ago I'd want the rest of me to stay alive. Sure it's a lousy way to live but it beats being all-the-way dead. Maybe if I make it 20 years they'll...
MRI bill question
May 15, 2013 Dear PFers, The hospital gave us a $12k bill for one MRI (head with contrast). The people I talked to at the hospital tell me that they do not...
Ratio of Hydrogen of Oxygen in Dessicated Animal Protein
May 13, 2013 As an experiment, for the past few months I've been consuming at least one portion of Jell-O or unflavored Knox gelatin per day. I'm 64, in very...
Alcohol and acetaminophen
May 13, 2013 Edit: sorry for the typo in the title , can't edit I looked around on google quite a bit and it's very hard to find precise information on the...
Marie Curie's leukemia
May 13, 2013 Does anyone know what might be the cause of Marie Curie's cancer
- More from Physics Forums - Medical Sciences
More news stories
Europe's medicines watchdog said Friday the benefits of acne drug Diane-35, also widely used as a contraceptive, outweigh the risk of developing blood clots in the veins—when correctly prescribed.
Medications 21 hours ago | not rated yet | 0
Singapore's Agency for Science, Technology and Research (A*STAR) and Switzerland's Cytos Biotechnology AG today announced that the first healthy volunteer has been dosed in a Phase 1 clinical trial with their ...
Medications 22 hours ago | not rated yet | 0
(Medical Xpress)—An aspirin a day may not always keep heart disease away, say two University of Florida cardiologists. But a new algorithm they have developed outlines factors physicians should weigh as ...
Medications May 16, 2013 | 3.5 / 5 (2) | 0 |
(HealthDay)—The U.S. Food and Drug Administration has approved new, lower-dose labeling for the popular sleep drug Ambien (zolpidem) in an effort to cut down on daytime drowsiness that could be a hazard ...
Medications May 15, 2013 | not rated yet | 0
Big names in medicine are set to give an upbeat assessment of the war on AIDS on Tuesday, 30 years after French researchers identified the virus that causes the disease.
6 hours ago | 5 / 5 (1) | 0
For combat veterans suffering from post-traumatic stress disorder, 'fear circuitry' in the brain never rests
Chronic trauma can inflict lasting damage to brain regions associated with fear and anxiety. Previous imaging studies of people with post-traumatic stress disorder, or PTSD, have shown that these brain regions can over-or ...
7 hours ago | not rated yet | 0 |
(Medical Xpress)—What if the quality of your work depends more on your focus on the piano keys or canvas or laptop than your musical or painting or computing skills? If target users can be convinced, they ...
19 hours ago | 3.7 / 5 (3) | 0 |
The neural machinery underlying our olfactory sense continues to be an enigma for neuroscience. A recent review in Neuron seeks to expand traditional ideas about how neurons in the olfactory bulb might encode information about ...
18 hours ago | not rated yet | 0 |
In 2008 researchers from the University of Southern Denmark showed that the drug thioridazine, which has previously been used to treat schizophrenia, is also a powerful weapon against antibiotic-resistant bacteria such as ...
16 hours ago | 3.7 / 5 (3) | 0 |